Today marks the 4-month anniversary of the date Jeff Gottfurcht, rheumatoid arthritis suffer, reached the summit of Mount Everest. And since that time, there has been a whirlwind of activity at his charity, the Jeffrey Gottfurcht Children’s Arthritis Foundation. In addition to celebrating his success and achieving national publicity, Jeff and his supporters have enjoyed realizing dreams for some very special children.

Now Jeff is focused on his next expedition – climbing Aconcagua, the tallest mountain on the South American continent. It stands 22,841 feet. He will begin this 2-week climb in January, 2012. Once again, Jeff will be challenged by high winds, freezing temperatures and brutal snowstorms, not unlike those he experienced on Everest. And as he did on Everest, Jeff will be armed with Nyloxin™ to help ease the pain of his RA.

Jeff explained. “As I am currently training to climb Aconcagua next year, the highest mountain in South America, Nyloxin continues to relieve the pain I have. A major portion of my training focuses on running and keeping my heart rate high, to try and mimic how the heart must compensate for less oxygen at high altitudes. Running the distances I do, and hiking the miles that I do, rain or shine, takes incredible discipline, and being able to have strong, reliable pain relief during these sessions, as well as at rest, is paramount. I use Nyloxin a couple of times each day, and it really works. The countdown is on for Aconcagua, and Nyloxin and I will be ready!”

4 months ago today, Jeff and Sherpa Danuru reached the 29,035-foot summit of Mount Everest

This new adventure is all part of Jeff’s goal to climb all Seven Summits of the tallest mountains on each continent on earth. It is his wish that his climbs continue to bring awareness to rheumatoid arthritis, and that the dreams of all the children suffering from juvenile arthritis are met.

Nutra Pharma continues to support Jeff and his foundation. It is our hope that others suffering with conditions that cause physical limitations and chronic pain, are inspired  by Jeff’s astonishing accomplishments. We look forward to January and tracking the details of Jeff’s climb.

 

Mount Aconcagua, Mendoza District of Argentina

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Jeffrey Gottfurcht Preparing for Next Climb", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Ancient Times

China uses cobra venom to treat opium addiction, liver, lung, esophageal and skin cancers as well as leukemia and arthritis. India uses Cobra venom as a tonic, aphrodisiac, hepatic stimulant and to revive collapsed patients.

1837

German-born homeopathic physician Constantine Hering writes the book Effects of Snake Poison (1837), introducing cobra venom in Europe.

1853

British physician John Rutherford Russell uses cobra venom as a homeopathic treatment for heart disease.

1894

French physician Albert Calmette (famous for the Bacillus Calmette-Guérin vaccine for tuberculosis) develops the first anti-venom.

1900

English homeopath, John Henry Clarke, publishes three-volume Materia Medica, listing the medicinal applications of various snake venoms and the proper dilution of cobra venom for the treatment of pain.

Early 1900s

Albert Calmette studies the use of cobra venom in mice to treat pain associated with cancer.

1904

Lamb and Hunter describe the paralytic and cytotoxic effects of cobra venom on the nervous system of monkeys.

1930

Cobra venom is clinically tested for its effectiveness to treat cancer, though the greatest benefit is observed in the amelioration of pain.

1935

Dr. David Macht publishes a clinical study in the US regarding the use of cobra venom as an analgesic and standardizes the potency of the drug.

1936

While doing research for the pharmaceutical company, Westcott, Hynson and Dunning, Dr. David Macht shows that cobra venom, when injected in minute doses, produces analgesic effects that are superior to morphine in treating pain.

1937

Bill Haast establishes the Miami Serpentaruim and begins to produce snake venom.

1937-1955

Dr Murray Sanders develops polio treatment using snake venom while teaching at Columbia University.

1938

Acceptance of homeopathic medicine, including cobra venom, is incorporated into the Food, Drug & Cosmetic Act sponsored by Royal Copeland, a US Senator at the time.

Time magazine publishes a story on the beneficial uses of venom for pain.

1939

Dr. Robert Rutherford shows that cobra venom could be employed when morphine is no longer effective or when patients become addicted to the opiate, as published in the New England Journal of Medicine.

1940

The American Medical Association publishes a preliminary report on the use of cobra venom for the treatment of pain.

1949

Bill Haast from the Miami Serpentarium agrees to supply Dr. Murray Sanders with snake venom for his research on modified neurotoxins.

1953

Cobra venom is used to experimentally treat Polio in monkeys.

1954

Murray Sanders, Manuel Soret and Benjamin Akin, from the University of Miami Depart of Microbiology, publish “Naja Flava Neurotoxoid Interference Late in Experimental Poliomyelitis.”

LW Oaks and JH Quinn publish “Cobra Venom in Ocular Therapy.”

1958

Dr. Murray Sanders uses modified neurotoxin to treat patients during Cuba’s outbreak of Polio.

Murray Sanders, Manuel Soret and Benjamin Akin publish, “Neurotoxoid Interference Principals in Pseudorabies Infection, in Vivo Activation of Aujeszky Virus.”

1966

Dr. Murray Sanders nominated for Nobel Prize in Medicine.

1972-1982

Sanders treats approximately 1400 Amyotrophic Lateral Sclerosis ALS (Lou Gehrig’s Disease) patients with Investigational New Drug Permission, granted by the FDA.

1975

Patent issued to Sanders for Modified Neurotoxin.

M Sanders and ON Fellowes publish “Use of Detoxified Snake Neurotoxin as a Partial Treatment for Amyotrophic Lateral Sclerosis” In Cancer Cytology.

1978

The Kunming Institute of Zoology in China introduces an analgesic made from purified cobra venom neurotoxins.

Patent issued to Murray Sanders for Modified Neurotoxin derived from Naja Genus Snake Venom.

1979

Patent issued to Murray Sanders for Potency and Atoxicity Test for Modified Neurotoxin.

1982

Patent issued to Bill Haast for Use of Snake Venoms for Treatment of Neurological and Related Disorders.

1983

JE Yourist, HG Hanes and KD Miller publish “Inhibition of Herpes Simplex Virus Replication by Cobra alpha-Neurotoxoid.”

1988

Patent issued to Bill Haast for Compositions for Treatment of Neurological and Related Disorders.

2000

A modified version of the Kunming Institute analgesic, called Fu Fang Ke Tong Ning is put on the market in China to treat pain. This drug is now also used for treatment of drug addiction in the Chinese province of Yunnan.

AIDs Research Alliance conducts a study with 7 patients using oral administration of modified cobratoxin.

2001

Investigators at the National Institute of Cancer in Milan, Italy participate in Chinese clinical trials to assess the efficacy of cobra toxins in controlling post-operative pain and moderate to severe cancer pain.

2004

Astra Zeneca’s cobra venom-based anticoagulant, ximelagatran (Exanta), is rejected by FDA.

2009

Nutra Pharma introduces Cobroxin® to the market. Made from Asian cobra venom, it is the first over-the-counter product to treat moderate to severe chronic pain.

2010

Nutra Pharma introduces Nyloxin™ for distribution.

2011

Nutra Pharma receives a patent for Cobratoxin for its use as an analgesic. Cobratoxin is a major neurotoxin component of cobra venom.

Today and Beyond

Researchers in China are examining the possibility that cobra venom can be used to treat drug addiction.

The Nutra Pharma subsidiary, ReceptoPharm, is currently focusing on developing cobra venom toxoids for use in neurological diseases.

 

 

 

 

 

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Timeline History of the Medicinal Uses of Cobra Venom", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Please check out our first-ever issue of NutraNews, a bi-monthly electronic newsletter from the Nutra Pharma Corporation, where we share all our important announcements, articles, interviews, photos and more. You can easily subscribe to get future issues via email automatically by signing up for E-Alerts on the Nutra Pharma website home page.

 

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " The Premier Issue of NutraNews Launched", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Last week the Florida Medical Examiners Commission released drug-related death statistics for the state. 2,710 prescription painkiller-related deaths were reported in 2010 as compared to 2,488 in 2009, close to a 9 percent increase. The drug Oxycodone, was responsible for the most deaths last year – 1,516. That is three times the number of deaths caused by cocaine. Earlier this week, Florida courts ordered the destruction of the hundreds of thousands of painkiller pills, voluntarily given up by physicians in pain clinics.

In contrast to the prescription drug-related deaths reported last week, it was also reported that the sale of Oxycodone decreased around 17 percent during the first five months of this year. Governor Rick Scott is hopeful that with the new Drug Database Laws in effect since May, 2011, those numbers will decrease even more. Scott has commented publicly that his brother has been struggling with drug addiction for many years, so he has personal reasons for his motivation to control prescription drug abuse.

Deaths from prescription narcotics can occur from adverse reactions to the drugs as well as overuse. When addicted to opiate based drugs, users tend to need more and more of these narcotics to keep withdrawal symptoms at bay. This is where the danger lies; excessive amounts of these drugs typically cause breathing problems, and death by respiratory failure can result.

Rik J. Deitsch, Chairman and CEO of Nutra Pharma commented, “The good news is that the public is more educated than ever before about the dangers of narcotics, and fortunately the new Florida Drug Database Laws are making it harder for people to abuse prescription painkillers. We at Nutra Pharma are doing our part to spread the word about the safety and effectiveness of Nyloxin™ in treating moderate to severe chronic pain. It’s non-addictive, non-narcotic, non-steroidal and it really works.”

 

 

 

 

 

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Prescription Painkiller Deaths Higher in Florida Last Year: Hope is On the Way for 2011", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

In an Investors Business Daily article last week entitled, “Dauntless Jeffrey Gottfurcht Beats Mountainous Odds,”  Jeff was featured for his Mount Everest climb and his use of Nyloxin™ to treat the pain and inflammation from his rheumatoid arthritis.  The article is both online and in print.

Jeff Gottfurcht and his Sherpa Danuru at 29,035 feet on the summit of Everest

 

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Nutra Pharma and Nyloxin™ in Investors Business Daily", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.